Nordea Investment Management reduced its holdings in AbbVie by 7.7% in Q4, now owning about $951 million worth of shares. Despite this, analysts remain optimistic, with a consensus price target of $253.15 and mostly buy or hold ratings. AbbVie reported strong Q4 earnings beating estimates and raised its 2026 guidance. The company also announced a quarterly dividend with a 3.4% yield. Recent insider sales and competitive pressures from new drugs have caused some stock volatility, but AbbVie's pipeline and collaborations suggest potential growth ahead.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
